Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 12
2004 9
2005 11
2006 22
2007 16
2008 18
2009 18
2010 15
2011 19
2012 18
2013 24
2014 19
2015 27
2016 17
2017 20
2018 12
2019 22
2020 32
2021 23
2022 20
2023 16
2024 14
2025 25
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

399 results

Results by year

Filters applied: . Clear all
Page 1
Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non-small cell lung cancer.
Cavaliere S, Fogolari M, Iuliani M, Foderaro S, Cortellini A, Simonetti S, Mingo EC, Calagna S, Russano M, Vincenzi B, Tonini G, Angeletti S, Pantano F. Cavaliere S, et al. Among authors: tonini g. J Transl Med. 2026 Jan 17;24(1):180. doi: 10.1186/s12967-025-07570-4. J Transl Med. 2026. PMID: 41547827 Free PMC article.
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.
Botticelli A, Cremolini C, Scagnoli S, Biffoni M, Lonardi S, Fornaro L, Guarneri V, De Giorgi U, Ascierto PA, Blandino G, D'Amati G, Aglietta M, Conte P, Crimini E, Ceracchi M, Pisegna S, Verkhovskaia S, Bordonaro R, Bracarda S, Butturini G, Del Mastro L, DeCensi A, Fabbri A, Fenocchio E, Gori S, Metro G, Pessino A, Pozzessere D, Puglisi F, Tamberi S, Zambelli A, Marino D, Capoluongo E, Cappuzzo F, Cerbelli B, Giannini G, Malapelle U, Mazzuca F, Nuti M, Pruneri G, Simmaco M, Strigari L, Tonini G, Martini N, Curigliano G, Marchetti P. Botticelli A, et al. Among authors: tonini g. Clin Cancer Res. 2026 Jan 6;32(1):45-55. doi: 10.1158/1078-0432.CCR-25-0430. Clin Cancer Res. 2026. PMID: 40833744 Free PMC article. Clinical Trial.
Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review.
Citarella F, Mingo EC, Fiorenti M, Russano M, Perrone G, La Cava G, Santo V, Vendittelli A, Brunetti L, Saracino C, Esposito L, Malgeri A, Ramella S, Vincenzi B, Tonini G, Cortellini A. Citarella F, et al. Among authors: tonini g. Clin Lung Cancer. 2025 Dec 22;27(2):59-68. doi: 10.1016/j.cllc.2025.12.006. Online ahead of print. Clin Lung Cancer. 2025. PMID: 41548383 Free article. Review.
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Pirrone C, Malapelle U, Pepe F, Lo Prinzi F, Nichetti F, Saborowski A, Antonuzzo L, Camera S, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Grandis C, Lavacchi D, Persano M, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, De Cobelli F, Ratti F, Daniel F, Tesini G, Masi G, Vogel A, Lonardi S, Rimini M, Fornaro L, Rimassa L, Casadei-Gardini A. Pirrone C, et al. Among authors: tonini g. Eur J Cancer. 2025 Nov 17;230:116035. doi: 10.1016/j.ejca.2025.116035. Epub 2025 Oct 3. Eur J Cancer. 2025. PMID: 41076988
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.
Prinzi FL, Salani F, Camera S, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Chiara P, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Polito MG, Di Giacomo E, Farinea G, Bartalini L, Grelli G, De Rosa A, Lavacchi D, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Tesini G, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Bekaii-Saab T, Fornaro L, Masi G, Vogel A, Lonardi S, Rimini M, Rimassa L, Casadei-Gardini A. Prinzi FL, et al. Among authors: tonini g. Int J Cancer. 2025 Nov 15;157(10):2092-2102. doi: 10.1002/ijc.70009. Epub 2025 Jul 11. Int J Cancer. 2025. PMID: 40641448 Free PMC article.
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Cortellini A, Garbo E, La Cava G, Citarella F, Santo V, Brunetti L, Pinato DJ, Naidoo J, Loza M, Genova C, Gettinger S, Kim SY, Jayakrishnan R, Zarif TE, Russano M, Pecci F, Di Federico A, Montrone M, Owen DH, Signorelli D, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Yendamuri S, Grossi F, Josephides E, Tomasik B, Giusti R, Bria E, Sebastian M, Rost M, Acker F, Landi L, Mazzoni F, Morabito A, Leonetti A, Cantini L, Mountzios G, Kalvapudi S, O'Reilly D, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Piedra A, Cortinovis DL, Tonini G, Minuti G, Mezquita L, Gorria T, Beninato T, Lo Russo G, PrelaJ A, De Giglio A, Biello F, Nana FA, Dingemans AC, Aerts JG, Ferrara R, Abu Hejleh T, Takada K, Naqash AR, Garassino MC, Wakelee HA, Nassar A, Ricciuti B, Soda P, Caruso CM, Guarrasi V. Cortellini A, et al. Among authors: tonini g. Lung Cancer. 2025 Nov;209:108799. doi: 10.1016/j.lungcan.2025.108799. Epub 2025 Oct 16. Lung Cancer. 2025. PMID: 41108882 Free article.
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results.
Morgillo F, Del Signore E, Bria E, de Marinis F, Ciardiello F, Garassino MC, Stefani A, Verderame F, Morabito A, Sbrana A, Tonini G, Gilli M, Berardi R, Taveggia PA, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Fadda GM, Iero M, Ardizzoni A. Morgillo F, et al. Among authors: tonini g. Clin Lung Cancer. 2025 Nov;26(7):541-551. doi: 10.1016/j.cllc.2025.07.003. Epub 2025 Jul 9. Clin Lung Cancer. 2025. PMID: 40738833 Free article. Clinical Trial.
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
Marchetti P, Curigliano G, Biffoni M, Lonardi S, Scagnoli S, Fornaro L, Guarneri V, De Giorgi U, Ascierto PA, Blandino G, D'Amati G, Aglietta M, Cremolini C, Conte P, Crimini E, Ceracchi M, Pisegna S, Verkhovskaia S, Bordonaro R, Bracarda S, Butturini G, Del Mastro L, DeCensi A, Fabbri A, Fenocchio E, Gori S, Metro G, Pessino A, Pozzessere D, Puglisi F, Tamberi S, Zambelli A, Marino D, Capoluongo E, Cappuzzo F, Cerbelli B, Giannini G, Malapelle U, Mazzuca F, Nuti M, Pruneri G, Simmaco M, Strigari L, Tonini G, Martini N, Botticelli A; ROME trial investigators consortia. Marchetti P, et al. Among authors: tonini g. Nat Med. 2025 Oct;31(10):3514-3523. doi: 10.1038/s41591-025-03918-x. Epub 2025 Sep 29. Nat Med. 2025. PMID: 41023484 Free PMC article. Clinical Trial.
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.
Antoniotti C, Marmorino F, Rossini D, Schmoll HJ, Lonardi S, Tonini G, Borelli B, Cupini S, Stein A, Moretto R, Bergamo F, Ronzoni M, Germani MM, Zaniboni A, Fazio R, De Grandis MC, Ongaro E, Masi G, Cremolini C. Antoniotti C, et al. Among authors: tonini g. Eur J Cancer. 2025 Oct 1;228:115713. doi: 10.1016/j.ejca.2025.115713. Epub 2025 Aug 15. Eur J Cancer. 2025. PMID: 40865392
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population.
Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Jae Chon H, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Malapelle U, Pepe F, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. Rimini M, et al. Among authors: tonini g. J Natl Cancer Inst. 2025 Oct 1;117(10):2029-2043. doi: 10.1093/jnci/djaf155. J Natl Cancer Inst. 2025. PMID: 40608977
399 results